T cell activation requires a T cell receptor (TCR) to recognize its cognate peptide in the context of an MHC molecule. In addition, the association of CD3 with the TCR–peptide–MHC complex ...

CD3 T-cell engagers (TCEs ... Preclinical studies have demonstrated robust T-cell activation, tumor growth inhibition, and overall therapeutic potential. ProBio's approach is supported by a ...

AbCellera’s poster presentation is available for download here. About AbCellera’s T-Cell Engager Platform CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment.

The European Commission (EC) has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic (linvoseltamab) for adults with relapsed and refractory (R/R) ...

Preclinical data on AbCellera’s PSMA x CD3 T-cell engagers demonstrate potent anti-tumor activity and potential to further enhance function through costimulatory strategies ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

AbCellera’s poster presentation is available for download here. About AbCellera’s T-Cell Engager Platform CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the ...

AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer Research Ⓡ (AACR) 116th Annual Meeting at ...